Carfilzomib
- PDF / 169,116 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 4 Downloads / 150 Views
1
S
Hepatitis B reactivation: case report In a recent EU review of clinical studies worldwide up to 10 July 2019, a patient [age and sex not stated] was described, who developed hepatitis B reactivation during treatment with carfilzomib [Kyprolis] in the post-marketing period. The patient had negative hepatitis B core antibodies (anti-HBc). The report was received from Medicines and Healthcare products Regulatory Agency. Author comment: "Of the 13 post-marketing cases in which baseline serology was reported: . . .1 case had negative anti-HBc". Medicines and Healthcare products Regulatory Agency. Carfilzomib (Kyprolis): risk of reactivation of hepatitis B virus Drug Safety Update 13: 5-6, No. 4, 27 Nov 2019. Available from: URL: https://assets.publishing.service.gov.uk/government/ uploads/system/uploads/attachment_data/file/847878/Nov-2019-PDF.pdf - United 803437912 Kingdom
0114-9954/19/1782-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 7 Dec 2019 No. 1782
Data Loading...
